Dongsung Pharmaceutical동성제약
002210 · KOSPI · ₩002210 · 동성제약
₩1,240▲ ₩19 (1.56%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 42.1% | 42.6% | 43.8% | 46.7% | 45.1% | 39.7% |
| Operating margin | −10.3% | −11.6% | −6.5% | 0.7% | −3.3% | −6.3% |
| Net margin | −15.6% | −29.5% | −16.5% | −2.3% | −2.3% | −5.1% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −5.8% | −1.4% | −0.2% | −5.1% | +10.6% | — |
| Operating income growth | +16.5% | −76.5% | −1,061.1% | +119.3% | +41.6% | — |
| Net income growth | +50.1% | −76.6% | −602.6% | +2.3% | +50.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −23.2% | −76.4% | −34.8% | −5.0% | −4.8% | −9.3% |
| Return on assets | −7.8% | −16.7% | −11.4% | −1.9% | −2.0% | −4.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 82.6% | 620.7% | 219.9% | 188.9% | 151.6% | 125.2% |
| Net debt to equity | 1.3% | 257.7% | 111.1% | 92.3% | 96.6% | 56.2% |
| Current ratio | 123.8% | 68.5% | 73.9% | 135.6% | 114.3% | 133.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Dongsung Pharmaceutical / 동성제약 / 002210 / KRX:002210
Source: KRX statistical information